康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

交易中 12-19 15:09:10

62.300

-1.300

-2.04%

最高63.350	最低60.750	成交量536.04万
今开61.700	昨收63.600	日振幅4.09%
总市值559.45亿	流通市值559.45亿	总股本8.98亿
成交额3.32亿	换手率0.60%	流通股本8.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":62.3,"timestamp":1734592129609,"preClose":63.6,"halted":0,"volume":5360364,"delay":0,"floatShares":898000000,"shares":898000000,"eps":2.5973985,"marketStatus":"交易中","marketStatusCode":2,"change":-1.3,"latestTime":"12-19 15:09:10","open":61.7,"high":63.35,"low":60.75,"amount":332186830,"amplitude":0.040881,"askPrice":62.35,"askSize":4000,"bidPrice":62.3,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.9376124139126918,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1734595800000},"adr":0,"listingDate":1587657600000,"adjPreClose":63.6,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.778245,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09926/wiki","defaultTab":"wiki","newsList":[{"id":"2492198509","title":"交银国际：医保工作会议再提丙类目录和支持商保发展 关注政策宽松相关机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2492198509","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492198509?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:31","pubTimestamp":1734571909,"startTime":"0","endTime":"0","summary":"全国医疗保障工作会议首提探索形成丙类目录。全国医疗保障工作会议共提出八大工作重点，其中多项措施明确支持商保发展。其中第五条“强化医保战略购买，赋能医药产业创新发展”指出，要“支持引导普惠型商业健康保险及时将创新药品纳入报销范围，研究探索形成丙类药品目录，并逐步扩大至其他符合条件的商业健康保险”。预计2025年，商保将有望迎来进一步发展，为解决创新药上市后的支付问题提供新的思路。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1515","BK1521","LU1794554557.SGD","BK1583","LU0417516571.SGD","09926","IE00BPRC5H50.USD","01952","BK1191","LU2488822045.USD","LU0348783233.USD","BK1147","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1589","BK1161","LU1720050803.USD","LU0348784397.USD","01177","BK1574","03329"],"gpt_icon":0},{"id":"2492891167","title":"【券商聚焦】交银国际预计2025年商保将有望进一步发展 协助解决创新药支付问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2492891167","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492891167?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:59","pubTimestamp":1734569982,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际预计2025年商保将有望进一步发展，协助解决创新药支付问题。同时，丙类目录+商保差异化发展的创新支付机制或缓解创新药械企业面临的进院难、报销支付难问题。近期医药板块在大幅震荡后有所回落，考虑到板块估值仍处于历史底部、叠加后续财政、医保/商保利好政策出台+流动性改善，该行认为仍有进一步修复空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK1589","LU0417516571.SGD","LU1720050803.USD","IE00B543WZ88.USD","09926","01177","BK1515","BK1521","159992","02096","06978","01952","BK1583","LU1794554557.SGD","BK1191","LU0348783233.USD","BK1147","LU0348784397.USD","BK1161","03329","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2492163114","title":"康方生物(9926.HK)：临床突破不断 全球潜力彰显","url":"https://stock-news.laohu8.com/highlight/detail?id=2492163114","media":"华泰证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492163114?lang=zh_cn&edition=full","pubTime":"2024-12-19 00:00","pubTimestamp":1734537600,"startTime":"0","endTime":"0","summary":"依沃西单抗在多个临床结果中展现了显著的治疗获益，尤其在HARMONi-2研究中头对头击败帕博利珠单抗，展现了全球重磅潜力。此外，依沃西单抗在NSCLC 围术期、头颈鳞癌、结直肠癌、TNBC 等II 期临床中展现良好疗效。此外，考虑到其他IO 联用抗血管生成的探索和依沃西单抗在部分瘤种的早期临床疗效，我们预计其适应症拓展将在海外展开，助推本品成为全球重磅级别品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219144711a1fa7aa2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219144711a1fa7aa2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","BK1161","LU0348783233.USD","LU0417516571.SGD","LU1720050803.USD","LU0348784397.USD","LU1794554557.SGD","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2492792979","title":"康方生物12月18日主力资金流入758万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492792979","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492792979?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:15","pubTimestamp":1734509748,"startTime":"0","endTime":"0","summary":"12月18日, 康方生物股价涨2.50%，报收63.60元，成交金额3.45亿元，换手率0.61%，振幅3.38%，量比0.61。康方生物今日主力资金净流入758万元，连续3日净流入，上一交易日主力净流入1012万元，今日环比减少25.10%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为61.11%，平均涨幅为3.38%。该股近5个交易日上涨0.95%，主力资金累计净流入3576万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1400万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218161612a1f7fe0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218161612a1f7fe0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","BK1161","LU0348783233.USD","LU0417516571.SGD","LU1720050803.USD","LU0348784397.USD","LU1794554557.SGD","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2492973333","title":"康方生物(09926)上涨2.82%，报63.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492973333","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492973333?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:12","pubTimestamp":1734505924,"startTime":"0","endTime":"0","summary":"12月18日，康方生物盘中上涨2.82%，截至15:12，报63.8元/股，成交3.0亿元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司，其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2024年中报，康方生物营业总收入10.25亿元、净利润-2.39亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/18151246531012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09926","LU0417516571.SGD","LU0348784397.USD","IE00B5MMRT66.SGD","LU1720050803.USD","BK1161","LU1794554557.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU0348783233.USD","IE00B543WZ88.USD","BK1574"],"gpt_icon":0},{"id":"2492947457","title":"港股通创新药ETF涨近1%，康方生物涨超3%，机构：“创新”+“出海”投资主线将贯穿明年","url":"https://stock-news.laohu8.com/highlight/detail?id=2492947457","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492947457?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:44","pubTimestamp":1734489877,"startTime":"0","endTime":"0","summary":"截至发稿，港股通创新药ETF涨0.84%，换手率2.74%，成交额超1700万元，盘中交投活跃。成分股方面，金斯瑞生物科技涨超4%，再鼎医药、康方生物涨超3%，药明生物、药明合联等个股跟涨。数据显示，截至12月17日收盘，港股通创新药ETF最新流通规模为6.40亿元，最新流通份额达6.76亿份。展望未来，机构预计“创新”和“出海”两条医药投资主线将贯穿2025年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218105511a1f7642e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218105511a1f7642e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","HSCEI","LU1720050803.USD","09926","HSTECH","LU0348784397.USD","LU1794554557.SGD","BK1161","LU0348783233.USD","LU0417516571.SGD","BK1574","LU2488822045.USD"],"gpt_icon":1},{"id":"2492342674","title":"康方生物12月16日获南向资金加仓133.50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492342674","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492342674?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:30","pubTimestamp":1734399024,"startTime":"0","endTime":"0","summary":"12月16日, 南向资金增持康方生物133.50万股。截止当日收盘，港股通共持有康方生物33854.05万股，占流通股37.71%。康方生物近5个交易日下跌6.93%，港股通累计增持504.33万股；近20个交易日下跌3.36%，港股通累计增持2111.12万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093334ab7dbf10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093334ab7dbf10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","BK1161","LU1720050803.USD","IE00BPRC5H50.USD","LU0417516571.SGD","BK1574","LU2488822045.USD","IE00B543WZ88.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0348783233.USD"],"gpt_icon":0},{"id":"2491630509","title":"医药股多数承压 来凯医药(02105)跌近11% 机构指板块当前已经处于业绩、政策和资金三重反转的进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2491630509","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491630509?lang=zh_cn&edition=full","pubTime":"2024-12-16 14:56","pubTimestamp":1734332198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股多数承压，来凯医药 跌10.94%，康诺亚跌6.07%，金斯瑞生物科技跌5.54%，科伦博泰生物跌4.96%，康方生物跌4.4%，药明生物跌3.15%。国金证券发研指，医药板块当前已经处于业绩、政策和资金三重反转的进程之中，对2025年医药板块上市公司营收利润增速回升、板块行情复苏有充分信心。医保局将指导各地及中选企业做好中选结果落地实施工作，确保全国患者于2025年4月用上本次集采中选产品。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","LU0516423091.SGD","BK1576","LU0456827905.SGD","02162","06990","LU0348735423.USD","LU0516422952.EUR","HK0000306685.HKD","IE00B0JY6N72.USD","LU0417516571.SGD","LU0823426308.USD","LU0359201612.USD","LU1242518857.USD","LU0572944931.SGD","LU1720050803.USD","HK0000320223.HKD","SG9999002463.SGD","LU0326950275.SGD","01548","09939","LU0051755006.USD","LU0456846285.SGD","LU0181495838.USD","09926","LU0516422366.SGD","LU1880383366.USD","LU0516423174.USD","IE00B5MMRT66.SGD","LU0588546209.SGD","BK1583","LU0320764599.SGD","LU0348825331.USD","LU0979878070.USD","HK0000306701.USD","BK1521","02105","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU1242518931.SGD","LU0140636845.USD","02269","BK1587","LU2039709279.SGD","LU0307460666.USD","LU0359202008.SGD","159938","BK1574","LU0823426480.USD"],"gpt_icon":1},{"id":"2491896246","title":"康方生物(09926)下跌5.11%，报60.4元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491896246","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491896246?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:46","pubTimestamp":1734313589,"startTime":"0","endTime":"0","summary":"12月16日，康方生物盘中下跌5.11%，截至09:46，报60.4元/股，成交1.76亿元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司，其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2024年中报，康方生物营业总收入10.25亿元、净利润-2.39亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/16094646408184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1720050803.USD","LU0348783233.USD","BK1161","BK1574","LU2488822045.USD","IE00BPRC5H50.USD","LU0348784397.USD","LU1794554557.SGD","09926","LU0417516571.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2491681810","title":"康方生物盘中异动 早盘急速下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491681810","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491681810?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:46","pubTimestamp":1734313586,"startTime":"0","endTime":"0","summary":"2024年12月16日早盘09时46分，康方生物股票出现异动，股价快速下挫5.11%。机构评级方面，在所有23家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。康方生物股票所在的生物技术行业中，整体跌幅为0.25%。消息层面，截至09时46分，《瑞银：重申康方生物“买入”评级 目标价升至88.1港元》资讯为影响康方生物的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216094626984c5674&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216094626984c5674&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","BK1161","LU0348784397.USD","LU0417516571.SGD","BK1574","LU1720050803.USD","IE00B543WZ88.USD","09926","LU0348783233.USD","LU2488822045.USD","IE00BPRC5H50.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2491686468","title":"南向资金12月13日净买入康方生物46.43万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2491686468","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491686468?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:30","pubTimestamp":1734312625,"startTime":"0","endTime":"0","summary":"12月13日, 南向资金增持康方生物46.43万股，连续7日增持。截止当日收盘，港股通共持有康方生物33720.55万股，占流通股37.56%。康方生物近5个交易日下跌2.38%，港股通累计增持448.43万股；近20个交易日下跌7.42%，港股通累计增持2009.12万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093334a1f1a8e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093334a1f1a8e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","IE00B543WZ88.USD","BK1161","IE00B5MMRT66.SGD","LU0348783233.USD","BK1574","LU1794554557.SGD","LU0417516571.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU1720050803.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2491343617","title":"康方生物12月13日主力资金流出189万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491343617","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491343617?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:16","pubTimestamp":1734077769,"startTime":"0","endTime":"0","summary":"12月13日, 康方生物股价跌3.41%，报收63.65元，成交金额4.72亿元，换手率0.82%，振幅4.40%，量比0.72。康方生物今日主力资金净流出189万元，连续5日净流出，上一交易日主力净流出122万元，今日环比增加54.92%。该股近5个交易日下跌1.84%，主力资金累计净流出4774万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出2687万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161652ab74c07a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213161652ab74c07a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348783233.USD","LU0348784397.USD","IE00B5MMRT66.SGD","BK1574","IE00B543WZ88.USD","09926","LU2488822045.USD","LU0417516571.SGD","LU1720050803.USD"],"gpt_icon":0},{"id":"2491234376","title":"康方生物(09926)出现大手卖出17.4万股，成交价$63.65，涉资1.108千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2491234376","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491234376?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:08","pubTimestamp":1734077280,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在下午04:08出现大手卖出，成交量为17.4万，成交价为港币$63.65，涉资1.108千万。至目前为止，股价跌3.414%，今日最高价为$65.9，而最低价为$63.0，总成交量为737.572万股，总成交金额港币$4.721亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2412136371/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","IE00B543WZ88.USD","LU0417516571.SGD","BK1161","LU0348783233.USD","BK1574","LU0348784397.USD","IE00BPRC5H50.USD","LU1720050803.USD","09926"],"gpt_icon":0},{"id":"2491139227","title":"瑞银：重申康方生物(09926)“买入”评级 目标价升至88.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491139227","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491139227?lang=zh_cn&edition=full","pubTime":"2024-12-13 11:37","pubTimestamp":1734061032,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研究报告称，重申康方生物(09926)“买入”评级，调高对公司近期产品销售增长和销售高峰的预测，目标价由68.7港元升至88.1港元。该行认为，康方生物在研发和商业化方面取得良好的进展，ivonescimab (AK112) HARMONi-2和cadonilimab (AK104) COMPASSION-15研究的积极结果提升了该行对其全球市场潜力的信心。报告中称，公司内地业务方面，除了即将获批的AK101(IL-12/23)外，相信AK112和AK104被纳入2024年国家医保药品目录(NRDL)将推动公司明年的产品销售增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926"],"gpt_icon":0},{"id":"2490806898","title":"专访康方生物联合创始人张鹏：2款首创新药纳入医保 期待全链条支持政策加速落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2490806898","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490806898?lang=zh_cn&edition=full","pubTime":"2024-12-12 18:39","pubTimestamp":1733999989,"startTime":"0","endTime":"0","summary":"2024年，康方生物传出多个好消息。先是依沃西单抗在一项“头对头”试验中显现出了超越K药（帕博利珠单抗）的临床疗效，证明了打败全球“药王”的潜力。后有卡度尼利、依沃西纳入医保目录，闯过了新药上市后的重要一关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412123266857690.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412123266857690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09926","BK1574","06978","LU0348784397.USD","LU1720050803.USD","LU1794554557.SGD","LU2488822045.USD","BK1161","IE00B543WZ88.USD","LU0417516571.SGD","LU0348783233.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2490879827","title":"【券商聚焦】浦银国际对2025年医药板块整体呈乐观态度 看好创新药、医疗器械及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879827","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490879827?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:52","pubTimestamp":1733989962,"startTime":"0","endTime":"0","summary":"2)医疗器械：看好创新高值耗材、医疗设备板块。康诺亚核心产品CM310将于2025年迎来首个完整年度商业化，作为首个国产重磅IL4R，该行认为其市场潜力巨大。此外，康诺亚研发实力强劲，NewCo形式有助于加快其出海步伐，2025年潜在出海交易有望进一步提振股票行情。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949533","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422366.SGD","159883","06978","02359","LU0359202008.SGD","LU1720050803.USD","SG9999002562.SGD","LU0823426308.USD","00013","BK1610","02190","LU0043850808.USD","BK1100","LU0307460666.USD","IE00B5MMRT66.SGD","LU0327786744.USD","159992","LU0348735423.USD","LU0979878070.USD","09939","02269","LU0417516738.SGD","LU0819121731.USD","01789","09997","LU2328871848.SGD","BK1191","LU0196878994.USD","159938","LU0572944931.SGD","LU0181495838.USD","02162","06990","02268","06160","BK1141","09996","BK1521","BK1589","03759","09926","CXO","LU0856984785.SGD","LU2125910500.SGD","LU0348784397.USD","LU2488822045.USD","LU2045819591.USD","SG9999002463.SGD","IE00B543WZ88.USD","SG9999014674.SGD"],"gpt_icon":1},{"id":"1145814303","title":"异动解读 | 康方生物(09926)成创新药标的 医药政策利好推动股价盘中大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145814303","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145814303?lang=zh_cn&edition=full","pubTime":"2024-12-12 14:40","pubTimestamp":1733985638,"startTime":"0","endTime":"0","summary":"康方生物(09926)今日盘中股价大涨5.06%,引发市场高度关注。主要原因如下:\n\n一方面,康方生物凭借创新药物管线初步展现出世界级潜力,被券商看好为未来医药行业的潜力标的。其产品卡度尼利一线宫颈癌、胃癌取得重要临床进展,有望弥补肿瘤免疫疗法的临床不足;依沃西单抗在多领域疗效显著,未来销售前景广阔。\n另一方面,政策面上,上海市发布文件提出设立100亿人民币生物医药产业并购基金,旨在推动行业创新发展和并购整合,利好行业龙头创新药标的走向资本市场。同时随着流动性改善、医保利好政策持续推出,或将推动医药行业估值获得修复。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 康方生物(09926)成创新药标的 医药政策利好推动股价盘中大涨5.06%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"gpt_icon":0},{"id":"2490827162","title":"康方生物盘中异动 下午盘股价大涨5.06%报66.450港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490827162","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490827162?lang=zh_cn&edition=full","pubTime":"2024-12-12 14:39","pubTimestamp":1733985571,"startTime":"0","endTime":"0","summary":"2024年12月12日下午盘14时39分，康方生物股票出现异动，股价快速拉升5.06%。截至发稿，该股报66.450港元/股，成交量849.46万股，换手率0.95%，振幅6.96%。资金方面，该股资金流入2.5137亿港元，流出1.94324亿港元。康方生物股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，思路迪医药股份、晶泰控股-P、帝王国际投资涨幅较大，振幅较大的相关个股有思路迪医药股份、晶泰控股-P、帝王国际投资，振幅分别为38.70%、19.44%、18.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212143931a1e84d72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212143931a1e84d72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1794554557.SGD","LU0348783233.USD","09926","IE00BPRC5H50.USD","LU0417516571.SGD","BK1161","LU1720050803.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1574","LU2488822045.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2490789824","title":"康方生物(09926)杨俊坚荣获“最佳PR奖”","url":"https://stock-news.laohu8.com/highlight/detail?id=2490789824","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490789824?lang=zh_cn&edition=full","pubTime":"2024-12-12 14:01","pubTimestamp":1733983299,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2024年12月11日，康方生物杨俊坚先生在备受瞩目的“第九届智通财经资本市场年会暨上市公司颁奖典礼”上荣获“最佳PR奖”。“最佳PR奖”，其主要表彰为公司建立了系统、有效的市场品牌及公共关系管理体系，使得公司与市场保持紧密、畅通的沟通交流，为公司树立了良好的市场公共形象的PR。康方生物杨俊坚先生此次获奖，不仅彰显了业界和投资者的对康方生物PR工作的认可，也是对公司极大的鼓励与鞭策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348783233.USD","BK4213","LU0348784397.USD","IE00B5MMRT66.SGD","BK1574","IE00B543WZ88.USD","09926","LU2488822045.USD","PR","LU0417516571.SGD","LU1720050803.USD"],"gpt_icon":0},{"id":"2490535822","title":"康方生物(09926)上涨2.06%，报64.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490535822","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490535822?lang=zh_cn&edition=full","pubTime":"2024-12-12 13:58","pubTimestamp":1733983121,"startTime":"0","endTime":"0","summary":"12月12日，康方生物盘中上涨2.06%，截至13:58，报64.55元/股，成交3.51亿元。康方生物科技(开曼)有限公司是一家主要从事研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司，其技术核心有Tetrabody双特异性抗体、抗体偶联技术、mRNA技术及细胞治疗技术。截至2024年中报，康方生物营业总收入10.25亿元、净利润-2.39亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/12135846305812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","09926","IE00BPRC5H50.USD","LU0417516571.SGD","LU1794554557.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0348784397.USD","LU2488822045.USD","BK1161","LU1720050803.USD","LU0348783233.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0047},{"period":"3month","weight":-0.0055},{"period":"6month","weight":0.784},{"period":"1year","weight":0.4308},{"period":"ytd","weight":0.3707}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家主要从事生物产品研发的投资控股公司。该公司专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。该公司的主要产品包括AK104、AK105、AK112及AK109。该公司于中国市场及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.000127},{"month":2,"riseRate":0.25,"avgChangeRate":-0.01324},{"month":3,"riseRate":0.25,"avgChangeRate":-0.055315},{"month":4,"riseRate":0.75,"avgChangeRate":0.01855},{"month":5,"riseRate":0.4,"avgChangeRate":0.001922},{"month":6,"riseRate":0.6,"avgChangeRate":0.140431},{"month":7,"riseRate":0.4,"avgChangeRate":-0.03083},{"month":8,"riseRate":0.4,"avgChangeRate":-0.010728},{"month":9,"riseRate":0.6,"avgChangeRate":0.062076},{"month":10,"riseRate":0.6,"avgChangeRate":0.094612},{"month":11,"riseRate":1,"avgChangeRate":0.105892},{"month":12,"riseRate":0.4,"avgChangeRate":0.05798}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}